Dr. Xiaowen Liu 刘晓文
Chief Physician, Associate Professor
Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive surgery for gastric tumors, including laparoscopic and robotic procedures. Focuses on stomach-preserving surgery, enhanced recovery after surgery, minimally invasive treatment for early-to-mid stage gastric cancer, and conversion therapy for advanced gastric cancer.
Dr. Liu holds a doctorate in oncology and has over 20 years of experience in gastric cancer surgery. Completed a one-year exchange at Duke University. Leads a team at Fudan University Shanghai Cancer Center. Recognized as a Shanghai Pujiang Talent.
Professional roles
- Secretary General, Gastric Cancer Professional Committee, Shanghai Anti-Cancer Association
- Member, Gastrointestinal Tumor Professional Committee, Shanghai Anti-Cancer Association
- Senior Editorial Board Member, Cancer Medicine
- Guest Editor, Frontiers in Immunology
Name order: in Chinese the family name comes first (Liu Xiaowen). Papers usually list the name as Xiaowen Liu or Liu X.
Selected publications
54 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Biol Macromol, 2026 (senior author): Unveiling the post-translational landscape of Claudins: Orchestrators of barrier integrity, signaling, and disease through dynamic modifications. PubMed 42603680
- Cancer Commun (Lond), 2026 (first author): Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China. PubMed 41625476
- Cancer Commun (Lond), 2024 (senior author): LncRNA-CCAT5-mediated crosstalk between Wnt/β-Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activity. PubMed 38010289
- Cancer Med, 2023 (senior author): Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients. PubMed 35621244
- Front Immunol, 2022 (senior author): Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer. PubMed 36203562
- Front Immunol, 2022 (senior author): Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer. PubMed 35769483
- Mol Med, 2022 (senior author): Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction. PubMed 35508972
- Mol Carcinog, 2020 (first author): Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer. PubMed 32367578
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion